Date: 07.12.2020
Dr. Nikolai Slavov, Professor at Northeastern University, Joins ProtiFi's Scientific Advisory Board
Nikolai Slavov is a professor at Northeastern University and an Allen Distinguished Investigator.
LOS ANGELES, CA, UNITED STATES, December 7, 2020
/EINPresswire.com/ -- Dr. Nikolai Slavov, Professor at Northeastern University and an Allen Distinguished Investigator, officially joined the Scientific Advisory Board of ProtiFi, LLC Thursday December 3rd, 2020. Prof. Dr. Slavov has pioneered high- throughput mass-spectrometry methods for quantifying proteins in single cells and develops new computational methods for analyzing and understanding single-cell proteomics and multimodal data.
“Prof. Dr. Slavov’s single-cell, analytical, bioinformatic and mathematics expertise is invaluable as ProtiFi makes metabolomics, proteomics, lipidomics, glycomics, transcriptomics and genomics accessible to the broadest possible medical and scientific audiences” explains ProtiFi’s Founder and CEO Dr. John P. Wilson, PhD. “We are honored to have him join and anticipate his knowledge and skills will help omics reach the next level to make real and tangible impacts on people’s health and wellness.”
ProtiFi, LLC was launched in 2015 by Founder and CEO
Dr. John P. Wilson, PhD to understand life beyond genes. In contrast to static DNA, which is the same in every organ, the structures and machinery of life are dynamic and change with age or in conditions of health and disease. From sample preparation to data analysis, ProtiFi solutions address the issues of reproducibility, sensitivity, speed, translation of data to meaning, and multiomics analysis of a single sample.
Dr. Nikolai Slavov, Ph.D., is a professor at Northeastern University and an Allen Distinguished Investigator. His group seeks principles in the coordination among protein synthesis, metabolism, cell growth and differentiation. The Slavov group has pioneered high-throughput mass-spectrometry methods for quantifying proteins in single cells and develops new computational methods to analyze and understand single-cell proteomics and multimodal data. The group obtained direct evidence for a new regulatory mechanism of protein synthesis (ribosome specialization) and continues to drive research in this emerging field supported by the NIH Director’s New Innovator Award.
Dr. Slavov received his undergraduate education from the Massachusetts Institute of Technology (MIT) in 2004. He pursued doctoral research in the Botstein laboratory at Princeton University, aiming to understand how cells coordinate their growth, gene expression, and metabolism. He discovered a simple mechanism that can account for the growth-rate dependent transcriptional responses across a wide range of growth conditions. After defending his dissertation in 2010, Dr. Slavov began a postdoctoral project in the van Oudenaarden laboratory at MIT, aiming to understand the Warburg effect, a hallmark of cancer cells characterized by the fermentation of glucose in the presence of enough oxygen to support respiration. This work demonstrated that aerobic glycolysis can reduce the energy demands associated with respiratory metabolism and stress survival and that, contrary to expectations and decades-long assumptions, exponential growth at a constant rate can represent not a single metabolic/physiological state but a continuum of changing states characterized by different metabolic fluxes. Following a lead from these experiments, Dr. Slavov obtained direct evidence for differential stoichiometry among core ribosomal proteins in unperturbed wild-type cells. His findings support the existence of ribosomes with distinct protein composition and physiological function that represent an explored layer of regulating gene expression. Most recently, the Slavov Laboratory developed methods for high-throughput Single Cell ProtEomics by Mass Spectrometry (SCoPE-MS and SCoPE2) and used them to quantify proteome heterogeneity during cell differentiation.
Prof. Dr. Slavov has received many honors and awards including the Allen Distinguished Investigator Award, the NIH Director’s New Innovator Award, the SPARC Award from the Broad Institute of MIT and Harvard, the Princeton University Dean’s Award, the IRCSET Postgraduate Research Fellowship, he was a Finalist in the Young European Entrepreneur Competition, the Princeton Graduate Fellowship, the MIT Undergraduate Fellowship, the Eureka Fellowship for Academic Excellence, the Bronze Medal in the 31st International Chemistry Olympiad and a National Diploma for Exceptional Achievements in Chemistry.
In alignment with the education aspect of ProtiFi’s mission, Prof. Dr. Slavov actively organizes community initiatives, such as the annual single-cell proteomics conference (
single-cell.net/), which is a highly interactive and interdisciplinary meeting. He also participates and contributes to organizing other leading conferences, including NeurIPS and HUPO.
Date: 27.10.2020
ProtiFi and Tecan announce collaborative partnership for integrated proteomics
ProtiFi and Tecan have partnered to create an integrated, highly scalable and easy-to-use proteomics workflow powered by the ProtiFi S-Trap™ sample preparation system and the Tecan Resolvex® A200 automated positive pressure workstation. The combined solution enables researchers to reproducibly prepare samples of all types for mass spectrometry-based proteomics.
Preparing samples for proteomics has traditionally required a time-consuming and error-prone multi-step workflow that, according to literature, causes 75 % of the overall variability in proteomics data. S-Trap sample processing run on the Resolvex A200 solves this problem, allowing researchers to prepare large numbers of proteomics samples rapidly and consistently. The joint system provides researchers with an automated, standardized, and optimized workflow that increases productivity and eliminates the need for method development, enabling users toobtain better results from higher quality, more reproducible and uniform sample preparation.
ProtiFi S-Trap sample processing is a revolutionary plate-based approach that eliminates many of the challenges of proteomics sample preparation, and has been cited hundreds of times in the analysis of samples as diverse as serum and dirt. S-Trap plates capture, concentrate and clean up samples, removing allcontaminating molecules, such as detergents, PEG, salts, Laemmli loading buffer and viral transport media. Samples are digested in the plate to generate assay-ready samples in just a few hours. In combination with the compact, benchtop Resolvex A200 positive pressure workstation, this offers affordable and high throughput automated proteomics sample preparation to laboratories for the first time. The Resolvex A200 system uses gas-based positive pressure to deliver maximum process reproducibility and uniformity across columns or wells, and automates accurate liquid dispensing for up to 11 protocol solvents – including the S-Trap denaturation, washing, binding and elution buffers – to ensure efficient clean-up, digestion and elution. The standard S-Trap proteomics protocols come preinstalled on the Resolvex A200 workstation, or users can create custom protocols optimized for unique needs, reducing processing times and enhancing analytical performance.
To learn more about the Resolvex A200 positive pressure workstation, go to diagnostics.tecan.com/positive-pressure-workstations
To learn more about S-Trap sample processing, go to https://www.protifi.com/s-trap
About ProtiFi
ProtiFi, LLC (www.protifi.com) innovates technologies to revolutionize omics research. By making omics approaches accessible, rapid and reproducible, ProtiFi solutions accelerate our understanding of biology and facilitate personalized medicine and precision health. ProtiFi specializes in the invention, development and commercialization of technologies to solve bottleneck issues in sample collection, sample preparation, sample workup and data analysis. With R&D and production laboratories on Long Island, New York, ProtiFi’s exclusive products include S-Trap™ kits for reproducible, efficient sample preparation, Tryp-N™ (“N-terminal trypsin”) for clarified MS/MS spectra and higher sensitivity, and SimpliFi™ (simplifi.protifi.com), an online data analysis engine to easily and interactively transform large omics data sets into meaning. ProtiFi technologies have been cited in hundreds of papers and have become the method of choice for research in core labs and CROs, academia, big pharma and especially in clinical proteomics.
About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2019, Tecan generated sales of CHF 637 million (USD 643 million; EUR 574 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).